Unknown

Dataset Information

0

Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle.


ABSTRACT: INTRODUCTION:Skeletal muscle ischemia-reperfusion injury (I-R) is a complex injury process that includes damage to the sarcolemmal membrane, contributing to necrosis and apoptosis. MG53, a muscle-specific TRIM family protein, has been shown to be essential for regulating membrane repair and has been shown to be protective against cardiac I-R and various forms of skeletal muscle injury. The purpose of this study was to determine if recombinant human MG53 (rhMG53) administration offered protection against I-R. METHODS:rhMG53 was administered to rats immediately before tourniquet-induced ischemia and again immediately before reperfusion. Two days later muscle damage was assessed histologically. RESULTS:rhMG53 offered no protective effect, as evidenced primarily by similar Evans blue dye inclusion in the muscles of rats administered rhMG53 or saline. CONCLUSIONS:Administration of rhMG53 does not offer protection against I-R in rat skeletal muscle. Additional studies are required to determine if the lack of a response is species-specific.

SUBMITTER: Corona BT 

PROVIDER: S-EPMC4028410 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle.

Corona Benjamin T BT   Garg Koyal K   Roe Janet L JL   Zhu Hua H   Park Ki Ho KH   Ma Jianjie J   Walters Thomas J TJ  

Muscle & nerve 20140601 6


<h4>Introduction</h4>Skeletal muscle ischemia-reperfusion injury (I-R) is a complex injury process that includes damage to the sarcolemmal membrane, contributing to necrosis and apoptosis. MG53, a muscle-specific TRIM family protein, has been shown to be essential for regulating membrane repair and has been shown to be protective against cardiac I-R and various forms of skeletal muscle injury. The purpose of this study was to determine if recombinant human MG53 (rhMG53) administration offered pr  ...[more]

Similar Datasets

| S-EPMC7518663 | biostudies-literature
| S-EPMC4512204 | biostudies-literature
| S-EPMC3008320 | biostudies-literature
| S-EPMC5749296 | biostudies-literature
| S-EPMC6959219 | biostudies-literature
| S-EPMC4760409 | biostudies-literature
| S-EPMC8786462 | biostudies-literature
| S-EPMC6345480 | biostudies-literature
| S-EPMC5447266 | biostudies-literature
| S-EPMC8347674 | biostudies-literature